Carl Gray, MD
Hematology & Oncology · Ogden, UTNPI 1598873382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 980 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations.
Across 980 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Genentech USA, Inc.$1K
- AstraZeneca$1K
- Pfizer$866
- Merck$850
- plus $11K from 54 others
Across 393 payments — averaging $6364.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$500K
- Novartis$436K
- Astrazeneca UK Limited$314K
- Regeneron$236K
- Amgen$195K
- AstraZeneca$169K
- plus $652K from 16 others
What the payments were for
- Travel & lodging$9815%
- Food & beverage$17,32690%
- Education$8875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Abraxane$124
How this compares
$19,194 in reported general payments places this provider in the 75th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 104 | $1,085,171 |
| CabometyxCabozantinib S-Malate | 29 | $736,199 |
| RevlimidLenalidomide | 36 | $601,947 |
| ErleadaApalutamide | 23 | $354,542 |
| KisqaliRibociclib Succinate | 19 | $293,231 |
| LynparzaOlaparib | 21 | $275,558 |
| InlytaAxitinib | 11 | $224,742 |
| XtandiEnzalutamide | 16 | $223,931 |
| ZarxioFilgrastim-Sndz | 13 | $36,517 |
| OrgovyxRelugolix | 13 | $35,330 |
| EliquisApixaban | 40 | $32,255 |
| XareltoRivaroxaban | 31 | $23,726 |
| LinzessLinaclotide | 11 | $6,122 |
| Letrozole | 125 | $2,975 |
| Abiraterone Acetate | 22 | $2,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $57 | $736,19929 claims |
| Bristol Myers SquibbRevlimid | $688 | $601,94736 claims |
| Johnson & JohnsonErleada, Xarelto | $462 | $378,26854 claims |
| NovartisKisqali | $2,201 | $293,23119 claims |
| AstraZenecaLynparza | $1,022 | $275,55821 claims |
| PfizerInlyta, Eliquis | $866 | $256,99751 claims |
| Astellas Pharma US IncXtandi | $802 | $223,93116 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $255 | $35,33013 claims |
| AbbVieLinzess | $192 | $6,12211 claims |
| Lilly USA, LLCOlanzapine | $362 | $49821 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $244 | $42763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Ogden
- Belisario ArangoOgden$374K
- Joshua RamsayOgden$14K
- David CasselOgden$2K
- James MasonOgden$1K
- Vincent HansenOgden$509
- Douglas SborovSalt Lake City$473K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.